We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $163M
1-Year Est. Return 240.43%
This Fund
S&P 500
This Quarter Est. Return
+12.31%
1 Year Est. Return
+240.43%
3 Year Est. Return
+409.28%
5 Year Est. Return
+142.09%
10 Year Est. Return
+4,071.98%
AUM
$127M
AUM Growth
-$10.4M
Cap. Flow
-$18.7M
Cap. Flow %
-14.71%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$18.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
1
DELISTED
Audentes Therapeutics, Inc
BOLD
$34.6M 27.2%
1,806,832
– –
AKAO
2
DELISTED
Achaogen Inc
AKAO
$27.9M 21.91%
1,281,152
– –
IMDZ
3
DELISTED
Immune Design Corp.
IMDZ
$21.3M 16.76%
2,208,210
– –
OCUL icon
4
Ocular Therapeutix
OCUL
$2.19B
$20.5M 16.15%
2,215,384
– –
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
$9.54M 7.51%
101,855
-305,561
-75% -$18.7M
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
$6.04M 4.75%
1,048,601
– –
VANI icon
7
Vivani Medical
VANI
$107M
$5.62M 4.42%
187,207
– –
OPGN
8
DELISTED
OpGen, Inc
OPGN
$1.65M 1.3%
26
– –

Similar funds

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
GF
Gimbal Financial Carmel, Indiana $163M AUM
ACM
Arrington Capital Management Miami, Florida $163M AUM
KFS
Krane Financial Solutions Calabasas, California $162M AUM
VB
Value Base Tel Aviv, Israel $162M AUM 2.31% 1-Year Est. Return
RWA
Reicon Wealth Advisors Atlanta, Georgia $162M AUM
CCM
Candelo Capital Management New York $162M AUM 112.87% 1-Year Est. Return
GCM
Generation Capital Management Pittsford, New York $163M AUM 42.22% 1-Year Est. Return

Versant Venture Management's Q2 2017 Portfolio in Review

As of Q2 2017, Versant Venture Management held 8 positions worth $127M, down 7.6% from $138M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $18.7M in Q2 2017, reducing 1 holding. Its largest reduction was Clovis Oncology, Inc., cutting an estimated $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Versant Venture Management's biggest Q2 2017 reduction was Clovis Oncology, Inc., cutting an estimated $18.7M.
  • Versant Venture Management's ten largest holdings make up 100% of its $127M portfolio in Q2 2017.
  • Versant Venture Management opened 0 new positions and closed 0 in Q2 2017.
  • Versant Venture Management's portfolio value fell 7.6% quarter-over-quarter to $127M.

Based on Versant Venture Management's 13F filing for Q2 2017, filed 2 Aug 2017.